IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1284-1292

  Adamopoulos, Iannis E ^a,b,c   Suzuki, Erika ^b   Chao, Cheng Chi ^a   Gorman, Dan ^a   Adda, Sarvesh ^a   Maverakis, Emanual ^d   Zarbalis, Konstantinos ^c,d   Geissler, Richard ^e   Asio, Agelio ^a   Blumenschein, Wendy M ^a   Mcclanahan, Terrill ^a   De Malefyt, Rene Waal ^a   Eric Gershwin, M ^b   Bowman, Edward P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR; RNA; CYTOKINE; IL17A PROTEIN, MOUSE;

ABSCESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE MARROW DERIVED MACROPHAGE; CELL ACTIVATION; COLLAGEN-INDUCED ARTHRITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDERMIS HYPERPLASIA; FEMALE; FLOW CYTOMETRY; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PARAKERATOSIS; PATHOGENESIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SPLEEN CELL; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; DISEASE MODEL; EPIDERMIS; EXPERIMENTAL ARTHRITIS; GENETICS; HYPERPLASIA; METABOLISM; PATHOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, PSORIATIC; BONE RESORPTION; CYTOKINES; DISEASE MODELS, ANIMAL; EPIDERMIS; GENE TRANSFER TECHNIQUES; HYPERPLASIA; INTERLEUKIN-17; MICE; OSTEOCLASTS; RANK LIGAND;

EID: 84934978126     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204782     Document Type: Article

References (37)

1. Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheum 2009;5:634-41.
2. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
3. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
4. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
5. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.
6. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129:2175-83.
7. Teunissen MB, Koomen CW, de Waal Malefyt R. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9.
8. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87.
9. Adamopoulos IE, Tessmer M, Chao CC, et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 2011;187:951-9.
10. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18:1069-76.
11. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339-50.
12. Nie H, Zheng Y, Li R, et al Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med 2013;19:322-8.
13. Lubberts E, Schwarzenberger P, Huang W, et al. Requirement of IL-17 receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005;175:3360-8.
14. van Hamburg JP, Corneth OBJ, Paulissen SMJ, et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis 2013;72:1700-7.
15. Wang C, Wu L, Bulek K, et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013;14:72-81.
16. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82.
17. Chen L, Wei XQ, Evans B, et al. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 2008;38:2845-54.
18. Adamopoulos IE, Chao CC, Geissler R, et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther 2010;12:R29.
19. El Malki K, Karbach SH, Huppert J, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Invest Dermatol 2013;133:441-51.
20. Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012;132:2466-9.
21. Gray EE, Ramirez-Valle F, Xu Y, et al. Deficiency in IL-17-committed V4 gammadelta T cells in a spontaneous Sox13-mutant CD45.1 congenic mouse substrain provides protection from dermatitis. Nat Immunol 2013;14:584-92.
22. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat. Biotech 2010;28:1287-9.
23. Chao CC, Chen SJ, Adamopoulos IE, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011;44:243-52.
24. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Gen 2003;4:638-49.
25. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7.
26. Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008;58:3705-9.
27. Huffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010;42:996-9.
28. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40.
29. Schwarzenberger P, Huang W, Ye P, et al. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol 2000;164:4783-9.
30. Codarri L, Gyulveszi G, Tosevski V, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011;12:560-7.
31. El-Behi M, Ciric B, Dai H, et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011;12:568-75.
32. Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7.
33. Van de Velde NC, Mottram PL, Powell MS, et al. Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunology letters 2010;130:82-8.
34. Steffen C. William John Munro and Munro's abscess, and Franz Kogoj and Kogoj's spongiform pustule. Am J Dermatopathol 2002;24:364-8.
35. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182:5836-45.
36. Schon M, Denzer D, Kubitza RC, et al. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J Invest Dermatol 2000;114:976-83.
37. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73:349-56.